{"disease":{"id":"cardiomyopathy","name":"Cardiomyopathy","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":28},"drugs":{"marketed":[{"drug_id":"tafamidis","indication_name":"Transthyretin related familial amyloid cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"tafamidis","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":"1430.0","mechanism":"Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"mavacamten","indication_name":"Obstructive hypertrophic cardiomyopathy (HCM)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Camzyos","generic_name":"MAVACAMTEN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"cardiac myosin","drug_class":"Cardiac Myosin Inhibitor [EPC]","quality_score":65,"revenue":"600","mechanism":"Mavacamten selectively inhibits cardiac myosin, reducing force-producing cross-bridge formation and improving cardiac function in HCM."},{"drug_id":"vyndaqel","indication_name":"Transthyretin related familial amyloid cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"Tafamidis Meglumine","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin (TTR)","drug_class":"Transthyretin stabilizer","quality_score":10,"revenue":null,"mechanism":"Tafamidis selectively stabilizes TTR tetramer by binding at thyroxine sites, slowing monomer dissociation."},{"drug_id":"tafamidis-test","indication_name":"Transthyretin related familial amyloid cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"tafamidis-test","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":null,"mechanism":"Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"myk-461","indication_name":"Obstructive hypertrophic cardiomyopathy (HCM)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Camzyos","generic_name":"MYK-461","company_name":"Myokardia Inc","drug_phase":"marketed","molecular_target":"Myosin-7","drug_class":"Cardiac Myosin Inhibitor [EPC]","quality_score":51,"revenue":null,"mechanism":"Camzyos works by inhibiting the Myosin-7 protein, which is involved in the thickening of heart muscle cells."},{"drug_id":"non-interventional-study","indication_name":"Cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non-Interventional Study","generic_name":"non-interventional-study","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase","drug_class":"Anticoagulant","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"non-interventional-study","indication_name":"Hypertrophic Cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non-Interventional Study","generic_name":"non-interventional-study","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase","drug_class":"Anticoagulant","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"razoxane","indication_name":"Doxorubicin Induced Cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Razoxin","generic_name":"RAZOXANE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Razoxin works by chelating iron and preventing the formation of free radicals that damage heart tissue."},{"drug_id":"acoramidis","indication_name":"cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Attruby","generic_name":"ACORAMIDIS","company_name":"Bridgebio Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Attruby works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"propranolol","indication_name":"Hypertrophic cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inderal","generic_name":"propranolol","company_name":"Generic (originally ICI/AstraZeneca)","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 2 group E member 1, 5-hydroxytryptamine receptor 6, Cytochrome P450 1A2","drug_class":"Non-selective beta-blocker","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"vyndamax","indication_name":"Transthyretin related familial amyloid cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"Tafamidis","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":null,"mechanism":"Vyndaqel stabilizes the Transthyretin protein, preventing its misfolding and aggregation into amyloid fibrils."},{"drug_id":"dexrazoxane","indication_name":"Doxorubicin Induced Cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zinecard","generic_name":"DEXRAZOXANE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA topoisomerase 2-alpha","drug_class":"Cytoprotective Agent","quality_score":10,"revenue":null,"mechanism":"Zinecard works by binding to metal ions and preventing them from causing damage to DNA during anthracycline treatment."},{"drug_id":"zinecard","indication_name":"Doxorubicin Induced Cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zinecard","company_name":"M.D. Anderson Cancer Center","drug_phase":"phase_1","molecular_target":"DNA topoisomerase 2-beta, DNA topoisomerase 2-alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"acoramidis","indication_name":"Cardiomyopathy of ATTR-CM","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Attruby","generic_name":"ACORAMIDIS","company_name":"Bridgebio Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Attruby works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"dehydrated-alcohol","indication_name":"Hypertrophic Obstructive Cardiomyopathy Treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"dehydrated alcohol","company_name":"American Medical Systems","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":"Dehydrated alcohol causes myocardial infarction by injecting it into a target septal vessel, leading to thinning of the hypertrophied septum."}],"pipeline":[{"drug_id":"vyndamax-tafamidis-61mg","indication_name":"ATTR-CM (Transthyretin Amyloid Cardiomyopathy)","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndamax (tafamidis 61mg)","generic_name":"vyndamax-tafamidis-61mg","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"As prescribed in real world practice","quality_score":0,"revenue":null,"mechanism":"As prescribed in real world practice"},{"drug_id":"treatment-for-ttr-amyloidosis","indication_name":"Transthyretin (TTR) Amyloid Cardiomyopathy","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Treatment for TTR amyloidosis","generic_name":"treatment-for-ttr-amyloidosis","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"The usual adult dose is 80 mg of Tafamidis Meglumine orally once daily. The dose may be reduced if n","quality_score":null,"revenue":null,"mechanism":"The usual adult dose is 80 mg of Tafamidis Meglumine orally once daily. The dose may be reduced if n"},{"drug_id":"tafamidis-61-milligrams","indication_name":"Transthyretin Amyloid Cardiomyopathy","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis 61 milligrams","generic_name":"tafamidis-61-milligrams","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"Tafamidis 61mg as provided in real-world practice","quality_score":null,"revenue":null,"mechanism":"Tafamidis 61mg as provided in real-world practice"}],"offLabel":[],"totalMarketed":15,"totalPipeline":3},"trials":{"data":[{"nct_id":"NCT05645952","title":"Association of Obesity and Cardiovascular Outcomes in Dilated Cardiomyopathy","phase":"","overall_status":"UNKNOWN","enrollment_count":30000,"lead_sponsor_name":"Ajou University School of Medicine","has_results":false},{"nct_id":"NCT05645939","title":"Association of Obesity and Cardiovascular Outcomes in Hypertrophic Cardiomyopathy","phase":"","overall_status":"UNKNOWN","enrollment_count":30000,"lead_sponsor_name":"Ajou University School of Medicine","has_results":false},{"nct_id":"NCT07340762","title":"Automated Reports Generation of Cardiovascular Magnetic Resonance Imaging","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Chinese Academy of Medical Sciences, Fuwai Hospital","has_results":false},{"nct_id":"NCT06883383","title":"Data Analysis and Evaluation of the Incidence of Life-threatening Ventricular Arrhythmias in Patients with Newly Diagnosed Cardiomyopathies of NICM or MI/CAD Origin PROTECTED from SCD by a WCD","phase":"","overall_status":"COMPLETED","enrollment_count":19598,"lead_sponsor_name":"Hannover Medical School","has_results":false},{"nct_id":"NCT06607471","title":"Multimodal and Multidisciplinary Approach to Optimize Diagnostic, Prognostic, and Therapeutic Management of Patients with Non-ischemic Cardiomyopathies and Arrhythmogenic-inflammatory Phenotypes: a Multicenter, Observational, Retrospective and Prospective Registry Study.","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Scientific Institute San Raffaele","has_results":false},{"nct_id":"NCT06328075","title":"Artificial Intelligence to Assist the Echocardiographic Identification of Transthyretin Cardiac Amyloidosis","phase":"","overall_status":"UNKNOWN","enrollment_count":15000,"lead_sponsor_name":"Algalarrondo Vincent","has_results":false},{"nct_id":"NCT07263204","title":"AI-Enabled Diagnosis and Prognosis of Hypertrophic Cardiomyopathy","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT06287892","title":"Diagnosis of HCM With AI-ECG","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT04189822","title":"Hearts in Rhythm Organization (HiRO)National Registry and Bio Bank","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":10000,"lead_sponsor_name":"University of British Columbia","has_results":false},{"nct_id":"NCT07336290","title":"One-stop Evaluation of Hypertrophic Cardiomyopathy in Cardiac Magnetic Resonance","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":10000,"lead_sponsor_name":"Minjie Lu","has_results":false},{"nct_id":"NCT06449079","title":"The PICM Risk Prediction Study - Application of AI to Pacing","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Guy's and St Thomas' NHS Foundation Trust","has_results":false},{"nct_id":"NCT05081115","title":"Stress Echo 2030: the Novel ABCDE-(FGLPR) Protocol to Define the Future of Imaging","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Fatebenefratelli Hospital","has_results":false},{"nct_id":"NCT00027170","title":"Technical Development of Cardiovascular Magnetic Resonance Imaging","phase":"","overall_status":"COMPLETED","enrollment_count":8781,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT03037632","title":"DCM Precision Medicine Study","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6500,"lead_sponsor_name":"Ray Hershberger","has_results":false},{"nct_id":"NCT03237494","title":"TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects","phase":"","overall_status":"COMPLETED","enrollment_count":5028,"lead_sponsor_name":"CENTOGENE GmbH Rostock","has_results":false},{"nct_id":"NCT07325968","title":"Cardiac MRI in Myocarditis and Inflammatory Cardiomyopathy","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":5000,"lead_sponsor_name":"Chinese Academy of Medical Sciences, Fuwai Hospital","has_results":false},{"nct_id":"NCT01143454","title":"Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT06748261","title":"AI-enabled Screening and Diagnosis of Cardiomyopathies Using Coronary CTA","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT05521451","title":"Clinical Cohort Study - TRUST","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Universitätsklinikum Hamburg-Eppendorf","has_results":false},{"nct_id":"NCT07077304","title":"EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT07428031","title":"French Registry: Late Gadolinium Enhancement in Hypertrophic Cardiomyopathy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT07276139","title":"PACEVALUE: Development of a Risk Score to Predict Pacing-Induced Cardiomyopathy in Patients Undergoing Pacemaker or ICD Implantation and Evaluation of Patient Outcomes and Cost-Effectiveness Across Different Healthcare Systems","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":4500,"lead_sponsor_name":"Insel Gruppe AG, University Hospital Bern","has_results":false},{"nct_id":"NCT02549664","title":"Exercise in Genetic Cardiovascular Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":4299,"lead_sponsor_name":"Yale University","has_results":false},{"nct_id":"NCT03754101","title":"Exome Sequencing Study in Cardiomyopathy to Identify New Risk Variants","phase":"","overall_status":"UNKNOWN","enrollment_count":4000,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT02696135","title":"The Chinese Hypertrophic Cardiomyopathy Study(CHCS)","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"China National Center for Cardiovascular Diseases","has_results":false},{"nct_id":"NCT06775665","title":"A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT06898762","title":"Creation of a National Multicenter Platform for the Study of Inflammatory Myocardial Disease: Pre-MYO Cohort","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia","has_results":false},{"nct_id":"NCT06381778","title":"Taiwan Registry of Hypertrophic Cardiomyopathy (THIC) Research Synopsis","phase":"","overall_status":"RECRUITING","enrollment_count":2600,"lead_sponsor_name":"Far Eastern Memorial Hospital","has_results":false},{"nct_id":"NCT04990297","title":"Cardiac Magnetic Resonance for Risk Stratification in Dilated Cardiomyopathy","phase":"","overall_status":"RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Chinese Academy of Medical Sciences, Fuwai Hospital","has_results":false},{"nct_id":"NCT07131371","title":"Stratification, Management, and Guidance of Hypertrophic Cardiomyopathy Patients Using Hybrid Digital Twin Solutions","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Tampere University","has_results":false},{"nct_id":"NCT07381894","title":"Multicentre Hypertrophic Cardiomyopathy Registry","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2500,"lead_sponsor_name":"University of Manchester","has_results":false},{"nct_id":"NCT06784687","title":"Evaluation of the Prevalence and Clinical Manifestation of SARS-CoV-2 Infection in a Population of Adult and Pediatric Patients With Congenital Heart Disease","phase":"","overall_status":"COMPLETED","enrollment_count":2376,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT02958098","title":"My Research Legacy Pilot Study","phase":"","overall_status":"TERMINATED","enrollment_count":2267,"lead_sponsor_name":"American Heart Association","has_results":false},{"nct_id":"NCT05650658","title":"Left vs Left Randomized Clinical Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":2136,"lead_sponsor_name":"Baylor College of Medicine","has_results":false},{"nct_id":"NCT04464655","title":"A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease","phase":"","overall_status":"RECRUITING","enrollment_count":2130,"lead_sponsor_name":"McGill University Health Centre/Research Institute of the McGill University Health Centre","has_results":false},{"nct_id":"NCT07358078","title":"DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT03076580","title":"An Integrative-\"Omics\" Study of Cardiomyopathy Patients for Diagnosis and Prognosis in China","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Beijing Institute of Heart, Lung and Blood Vessel Diseases","has_results":false},{"nct_id":"NCT05884892","title":"Egyptian Hypertrophic Cardiomyopathy Program","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Magdi Yacoub Heart Foundation","has_results":false},{"nct_id":"NCT06964464","title":"Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"University of Rochester","has_results":false},{"nct_id":"NCT07354646","title":"The Application of T1 Mapping in Real-World","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Chinese Academy of Medical Sciences, Fuwai Hospital","has_results":false},{"nct_id":"NCT07527715","title":"Cardiac Magnetic Resonance-Clinical Prediction Model-Dilated Cardiomyopathy","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Shandong Provincial Hospital","has_results":false},{"nct_id":"NCT07110818","title":"Non-ischemic Cardiomyopathy Registry, Biobank and Imaging Data Repository","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Montreal Heart Institute","has_results":false},{"nct_id":"NCT03843255","title":"Defining the Genetics, Biomarkers and Outcomes for Dilated Cardiomyopathy","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT07235462","title":"A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05100420","title":"Hypertrophic Cardiomyopathy Registry, Biobank and Imaging Data Repository","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":2000,"lead_sponsor_name":"Montreal Heart Institute","has_results":false},{"nct_id":"NCT06338839","title":"Transthyretin Amyloidosis Cardiomyopathy in Patients With HFpEF in Russia","phase":"","overall_status":"TERMINATED","enrollment_count":1770,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02791230","title":"Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1733,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04303364","title":"CARdiomyopathy in Type 2 DIAbetes Mellitus","phase":"","overall_status":"RECRUITING","enrollment_count":1600,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT05489705","title":"A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)","phase":"","overall_status":"RECRUITING","enrollment_count":1600,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}